Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...

Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

The 35-year-old software developer, based in China's western metropolis of Chengdu, is about to start his third month on Ozempic, the brand name that pharmaceutical giant Novo Nordisk gives to ...

Weight loss drugs linked to dozens of deaths - The medical director of the NHS has warned of the side effects of weight loss ...

Even a little weight loss can work wonders for your health. A study found that people at high risk for developing type 2 diabetes who lost 5 to 7 percent of their weight had a 58% lower risk of ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

On Friday, the Food and Drug Administration declared the semaglutide shortage over, sending Hims & Hers shares down 26%.

The shortages were declared in August 2022. Meanwhile, Axios reports on how makers of copycat weight loss drugs are preparing for a crackdown. In medical tech and pharma news: a pacemaker recall, the ...

The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list. The U.S. Food and Drug ...